Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J1885
15 MG
Medicare payment limit per unit (Q4 2026): $0.569
| Setting | Max units / day | Adjudication (MAI) | CMS rationale |
|---|---|---|---|
| Practitioner services (professional claims) | 8 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
| Facility outpatient hospital services | 8 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
| DME supplier services | 0Not reportable in this setting | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. |
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$0.569per 15 MG
Effective Oct 1, 2026 – Dec 31, 2026 · ASP methodology (per CMS file) · based on Q2 2026 ASP data · coinsurance 20.000%
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $0.569 | 15 MG | 20% | +99.0% | — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $0.286 | 15 MG | 20% | −16.1% |
Medicare hospital outpatient (OPPS) · Q4 2026
K1 See CMS Addendum D1
$0.569 per unit · APC 0764 · copayment $0.120 per unit
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 50090-1328-01 | Ketorolac TromethamineA-S Medication Solutions | 2 × 1 | 4 | 4 | $2.28 | ASP | Q1 2024 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 50090-3364-00 | Ketorolac TromethamineA-S Medication Solutions | 1 × 25 | 2 | 50 | $28.45 | ASP | Q1 2021 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 50090-3364-01 | Ketorolac TromethamineA-S Medication Solutions | 1 × 25 | 2 | 50 | $28.45 | ASP | Q1 2021 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 50090-3397-01 | Ketorolac TromethamineA-S Medication Solutions | 2 × 25 | 4 | 100 | $56.90 | ASP | Q1 2021 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 50090-4583-00 | Ketorolac TromethamineA-S Medication Solutions | 2 × 25 | 4 | 100 | $56.90 | ASP | Q1 2021 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 50090-4635-00 | Ketorolac TromethamineA-S Medication Solutions | 2 × 25 | 4 | 100 | $56.90 | ASP | Q1 2021 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 50090-4635-01 | Ketorolac TromethamineA-S Medication Solutions | 2 × 1 | 4 | 4 | $2.28 | ASP | Q1 2021 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 50090-5013-00 | Ketorolac TromethamineA-S Medication Solutions | 1 × 25 | 2 | 50 | $28.45 | ASP | Q4 2021 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 50090-5013-01 | Ketorolac TromethamineA-S Medication Solutions | 1 × 1 | 2 | 2 | $1.14 | ASP | Q3 2021 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 50090-5428-00 | Ketorolac TromethamineA-S Medication Solutions | 1 × 25 | 2 | 50 | $28.45 | ASP | Q3 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 50090-5428-01 | Ketorolac TromethamineA-S Medication Solutions | 1 × 1 | 2 | 2 | $1.14 | ASP | Q3 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 50090-5609-00 | Ketorolac TromethamineA-S Medication Solutions | 1 × 25 | 1 | 25 | $14.22 | ASP | Q2 2022 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 50090-6772-00 | Ketorolac TromethamineA-S Medication Solutions | 2 × 25 | 4 | 100 | $56.90 | ASP | Q2 2024 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 50090-6772-01 | Ketorolac TromethamineA-S Medication Solutions | 2 × 1 | 4 | 4 | $2.28 | ASP | Q2 2024 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 50090-6807-00 | Ketorolac TromethamineA-S Medication Solutions | 1 × 25 | 1 | 25 | $14.22 | ASP | Q2 2024 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 62332-0599-25 | Ketorolac TromethamineAlembic Pharmaceuticals Inc. | 1 × 25 | 1 | 25 | $14.22 | ASP | Q4 2023 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 62332-0600-25 | Ketorolac TromethamineAlembic Pharmaceuticals Inc. | 1 × 25 | 2 | 50 | $28.45 | ASP | Q4 2023 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 62332-0601-25 | Ketorolac TromethamineAlembic Pharmaceuticals Inc. | 2 × 25 | 4 | 100 | $56.90 | ASP | Q4 2023 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 70860-0700-02 | Ketorolac TromethamineAthenex Pharmaceutical Division, LLC | 1 × 25 | 1 | 25 | $14.22 | ASP | Q1 2021 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 70860-0701-03 | Ketorolac TromethamineAthenex Pharmaceutical Division, LLC | 1 × 25 | 2 | 50 | $28.45 | ASP | Q1 2021 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 70860-0701-04 | Ketorolac TromethamineAthenex Pharmaceutical Division, LLC | 2 × 25 | 4 | 100 | $56.90 | ASP | Q1 2021 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 00338-0069-10 | Ketorolac TromethamineBaxter Healthcare Corporation | 1 × 10 | 1 | 10 | $5.69 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 00338-0072-25 | Ketorolac TromethamineBaxter Healthcare Corporation | 1 × 25 | 2 | 50 | $28.45 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 65145-0145-25 | Ketorolac TromethamineCaplin Steriles USA Inc. | 1 × 25 | 2 | 50 | $28.45 | ASP | Q3 2025 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 65145-0146-25 | Ketorolac TromethamineCaplin Steriles USA Inc. | 1 × 25 | 1 | 25 | $14.22 | ASP | Q3 2025 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 65145-0147-25 | Ketorolac TromethamineCaplin Steriles USA Inc. | 2 × 25 | 4 | 100 | $56.90 | ASP | Q3 2025 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 72572-0354-10 | Ketorolac TromethamineCivica, Inc. | 1 × 10 | 1 | 10 | $5.69 | ASP | Q1 2024 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 72572-0355-25 | Ketorolac TromethamineCivica, Inc. | 1 × 25 | 2 | 50 | $28.45 | ASP | Q1 2024 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 72572-0356-25 | Ketorolac TromethamineCivica, Inc. | 1 × 25 | 1 | 25 | $14.22 | ASP | Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 72266-0118-25 | Ketorolac TromethamineFosun Pharma USA Inc. | 1 × 25 | 2 | 50 | $28.45 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 72266-0119-25 | Ketorolac TromethamineFosun Pharma USA Inc. | 2 × 25 | 4 | 100 | $56.90 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 72266-0234-25 | Ketorolac TromethamineFosun Pharma USA Inc. | 1 × 25 | 1 | 25 | $14.22 | ASP | Q1 2024 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 63323-0161-01 | Ketorolac TromethamineFreseniUS Kabi USA, LLC | 1 × 25 | 1 | 25 | $14.22 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 63323-0161-12 | Ketorolac TromethamineFreseniUS Kabi USA, LLC | 1 × 25 | 1 | 25 | $14.22 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 63323-0161-16 | Ketorolac TromethamineFreseniUS Kabi USA, LLC | 1 × 25 | 1 | 25 | $14.22 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 63323-0162-01 | Ketorolac TromethamineFreseniUS Kabi USA, LLC | 1 × 25 | 2 | 50 | $28.45 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 63323-0162-02 | Ketorolac TromethamineFreseniUS Kabi USA, LLC | 2 × 25 | 4 | 100 | $56.90 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 63323-0162-12 | Ketorolac TromethamineFreseniUS Kabi USA, LLC | 1 × 25 | 2 | 50 | $28.45 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 63323-0162-14 | Ketorolac TromethamineFreseniUS Kabi USA, LLC | 2 × 25 | 4 | 100 | $56.90 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 63323-0162-16 | Ketorolac TromethamineFreseniUS Kabi USA, LLC | 1 × 25 | 2 | 50 | $28.45 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 63323-0162-26 | Ketorolac TromethamineFreseniUS Kabi USA, LLC | 2 × 25 | 4 | 100 | $56.90 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 76045-0104-10 | Ketorolac TromethamineFreseniUS Kabi USA, LLC | 1 × 24 | 2 | 48 | $27.31 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 76045-0105-20 | Ketorolac TromethamineFreseniUS Kabi USA, LLC | 2 × 24 | 4 | 96 | $54.62 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 76045-0209-10 | Ketorolac TromethamineFreseniUS Kabi USA, LLC | 1 × 24 | 2 | 48 | $27.31 | ASP | Q2 2022 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 68462-0755-25 | Ketorolac TromethamineGlenmark Pharmaceuticals Inc., USA | 1 × 25 | 1 | 25 | $14.22 | ASP | Q3 2024 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 68462-0756-25 | Ketorolac TromethamineGlenmark Pharmaceuticals Inc., USA | 1 × 25 | 2 | 50 | $28.45 | ASP | Q3 2024 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 68462-0757-25 | Ketorolac TromethamineGlenmark Pharmaceuticals Inc., USA | 2 × 25 | 4 | 100 | $56.90 | ASP | Q1 2025 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 00404-9952-01 | Ketorolac TromethamineHenry Schein Inc. | 1 × 1 | 1 | 1 | $0.57 | ASP | Q3 2023 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 00404-9996-01 | Ketorolac TromethamineHenry Schein Inc. | 1 × 1 | 2 | 2 | $1.14 | ASP | Q1 2024 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 00404-9997-02 | Ketorolac TromethamineHenry Schein Inc. | 2 × 1 | 4 | 4 | $2.28 | ASP | Q1 2024 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 00404-9998-01 | Ketorolac TromethamineHenry Schein Inc. | 1 × 1 | 1 | 1 | $0.57 | ASP | Q4 2024 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 51662-1292-01 | Ketorolac TromethamineHF Acquisition Co. LLC, DBA HealthFirst | 1 × 1 | 2 | 2 | $1.14 | ASP | Q4 2023 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 51662-1292-03 | Ketorolac TromethamineHF Acquisition Co. LLC, DBA HealthFirst | 1 × 25 | 2 | 50 | $28.45 | ASP | Q4 2023 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 51662-1295-01 | Ketorolac TromethamineHF Acquisition Co. LLC, DBA HealthFirst | 2 × 1 | 4 | 4 | $2.28 | ASP | Q4 2023 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 51662-1295-03 | Ketorolac TromethamineHF Acquisition Co. LLC, DBA HealthFirst | 2 × 25 | 4 | 100 | $56.90 | ASP | Q1 2024 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 51662-1594-03 | Ketorolac TromethamineHF Acquisition Co. LLC, DBA HealthFirst | 1 × 25 | 2 | 50 | $28.45 | ASP | Q4 2023 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 00487-6232-01 | Ketorolac TromethamineNephron SC, Inc. | 2 × 30 | 4 | 120 | $68.28 | ASP | Q4 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 72603-0153-25 | Ketorolac TromethamineNorthstar RxLLC | 1 × 25 | 1 | 25 | $14.22 | ASP | Q3 2024 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 72603-0161-25 | Ketorolac TromethamineNorthstar RxLLC | 1 × 25 | 2 | 50 | $28.45 | ASP | Q1 2026 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 00409-3793-01 | Ketorolac TromethaminePfizer Inc | 1 × 25 | 1 | 25 | $14.22 | ASP | Q1 2021 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 00409-3793-25 | Ketorolac TromethaminePfizer Inc | 1 × 25 | 1 | 25 | $14.22 | ASP | Q3 2025 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 00409-3795-01 | Ketorolac TromethaminePfizer Inc | 1 × 25 | 2 | 50 | $28.45 | ASP | Q1 2021 – Q4 2026 | Excluded listingKETOROLAC TROMETHAMINE |
| 00409-3795-25 | Ketorolac TromethaminePfizer Inc | 1 × 25 | 2 | 50 | $28.45 | ASP | Q3 2026 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 00409-3796-01 | Ketorolac TromethaminePfizer Inc | 2 × 25 | 4 | 100 | $56.90 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 00409-3796-25 | Ketorolac TromethaminePfizer Inc | 2 × 25 | 4 | 100 | $56.90 | ASP | Q3 2025 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 25021-0700-01 | Ketorolac TromethamineSagent Pharmaceuticals | 1 × 25 | 1 | 25 | $14.22 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 25021-0701-01 | Ketorolac TromethamineSagent Pharmaceuticals | 1 × 25 | 2 | 50 | $28.45 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 25021-0701-02 | Ketorolac TromethamineSagent Pharmaceuticals | 2 × 25 | 4 | 100 | $56.90 | ASP | Q1 2021 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 70512-0842-25 | Ketorolac TromethamineSola Pharmaceuticals | 1 × 25 | 1 | 25 | $14.22 | ASP | Q1 2026 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 70512-0843-25 | Ketorolac TromethamineSola Pharmaceuticals | 1 × 25 | 2 | 50 | $28.45 | ASP | Q1 2026 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
| 70512-0844-25 | Ketorolac TromethamineSola Pharmaceuticals | 2 × 25 | 4 | 100 | $56.90 | ASP | Q1 2026 – Q4 2026 | ListedKETOROLAC TROMETHAMINE |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 72611-0719-25 | Ketorolac TromethamineAlmaject, Inc. | 1 × 25 | 1 | 25 | ASP | Q1 2021 – Q3 2026Not in Q4 2026 file |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q2 2025 | Dates changed | N — No maintenance | Added Jan 1, 1993 · action effective Jan 1, 2025 · termination — |
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 1993 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| CMS Policy |
An MUE is the most units CMS expects for this code for one patient on one date of service by the same provider in most correctly reported claims. CMS MUE program
| — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $0.341 | 15 MG | 20% | +2.4% | — |
|---|
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $0.333 | 15 MG | 20% | +9.9% | — |
|---|
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $0.303 | 15 MG | 20% | −12.4% | — |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $0.346 | 15 MG | 20% | −30.9% | — |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $0.501 | 15 MG | 20% | −33.3% | — |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $0.751 | 15 MG | 20% | +10.1% | — |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $0.682 | 15 MG | 20% | −18.1% | — |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $0.833 | 15 MG | 20% | +18.7% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $0.702 | 15 MG | 20% | +43.9% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $0.488 | 15 MG | 20% | −19.3% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $0.605 | 15 MG | 20% | +10.8% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $0.546 | 15 MG | 20% | +12.1% | — |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $0.487 | 15 MG | 20% | −18.0% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $0.594 | 15 MG | — | −6.6% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $0.636 | 15 MG | — | −2.8% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $0.654 | 15 MG | — | +40.3% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $0.466 | 15 MG | — | −14.5% | — |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $0.545 | 15 MG | — | +12.8% | — |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $0.483 | 15 MG | — | +21.1% | — |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $0.399 | 15 MG | — | −38.3% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $0.647 | 15 MG | — | +67.6% | — |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $0.386 | 15 MG | — | — | — |
|---|
| 72611-0722-25 | Ketorolac TromethamineAlmaject, Inc. | 1 × 25 | 2 | 50 | ASP | Q1 2022 – Q4 2025Not in Q4 2026 file | Excluded listingKETOROLAC TROMETHAMINE |
|---|
| 72611-0725-25 | Ketorolac TromethamineAlmaject, Inc. | 2 × 25 | 4 | 100 | ASP | Q2 2021 – Q4 2025Not in Q4 2026 file | Excluded listingKETOROLAC TROMETHAMINE |
|---|
| 47781-0583-68 | Ketorolac TromethamineALVOGEN | 1 × 25 | 1 | 25 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingKETOROLAC TROMETHAMINE |
|---|
| 47781-0584-68 | Ketorolac TromethamineALVOGEN | 1 × 25 | 2 | 50 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingKETOROLAC TROMETHAMINE |
|---|
| 47781-0585-68 | Ketorolac TromethamineALVOGEN | 2 × 25 | 4 | 100 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingKETOROLAC TROMETHAMINE |
|---|
| 70860-0700-01 | Ketorolac TromethamineATHENEX | 1 × 10 | 1 | 10 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingKETOROLAC TROMETHAMINE |
|---|
| 70860-0701-01 | Ketorolac TromethamineATHENEX | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingKETOROLAC TROMETHAMINE |
|---|
| 70860-0701-02 | Ketorolac TromethamineATHENEX | 2 × 10 | 4 | 40 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingKETOROLAC TROMETHAMINE |
|---|
| 76045-0107-10 | Ketorolac TromethamineFRESENIUS KABI | 1 × 24 | 1 | 24 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | ListedKETOROLAC TROMETHAMINE |
|---|
| 00404-9883-01 | Ketorolac TromethamineHENRY SCHEIN, INC. | 1 × 1 | 2 | 2 | ASP | Q4 2023 – Q4 2024Not in Q4 2026 file | Excluded listingKETOROLAC TROMETHAMINE |
|---|
| 00404-9884-02 | Ketorolac TromethamineHENRY SCHEIN, INC. | 2 × 1 | 4 | 4 | ASP | Q4 2023 – Q4 2024Not in Q4 2026 file | Excluded listingKETOROLAC TROMETHAMINE |
|---|
| 52584-0722-01 | Ketorolac TromethamineHENRY SCHEIN, INC. | 1 × 1 | 2 | 2 | ASP | Q3 2023 – Q4 2024Not in Q4 2026 file | Excluded listingKETOROLAC TROMETHAMINE |
|---|
| 00641-6041-25 | Ketorolac TromethamineHIKMA PHARMACEUTICALS USA INC. | 1 × 25 | 1 | 25 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | ListedKETOROLAC TROMETHAMINE |
|---|
| 00641-6042-25 | Ketorolac TromethamineHIKMA PHARMACEUTICALS USA INC. | 1 × 25 | 2 | 50 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | ListedKETOROLAC TROMETHAMINE |
|---|
| 00641-6043-25 | Ketorolac TromethamineHIKMA PHARMACEUTICALS USA INC. | 2 × 25 | 4 | 100 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | ListedKETOROLAC TROMETHAMINE |
|---|
| 00409-2287-23 | Ketorolac TromethaminePFIZER INC. | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q2 2021Not in Q4 2026 file | Excluded listingKETOROLAC TROMETHAMINE |
|---|
| 00409-2287-31 | Ketorolac TromethaminePFIZER INC. | 1 × 10 | 2 | 20 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingKETOROLAC TROMETHAMINE |
|---|
| 00409-2287-61 | Ketorolac TromethaminePFIZER INC. | 2 × 10 | 4 | 40 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingKETOROLAC TROMETHAMINE |
|---|